Sector News

J&J buying Vogue Int’l for about $3.3B

June 3, 2016
Life sciences

Johnson & Johnson is buying hair care products maker Vogue International for about $3.3 billion.

Privately-held Vogue also sells other personal care products.

The acquisition will give Johnson & Johnson the OGX collection of shampoos, conditioners, treatments, styling products, body care and bath products, the FX hair styling product line and the Proganix and Maui Moisture hair care lines.

Vogue’s hair care products are sold in the U.S. and 38 other countries.

Johnson & Johnson, based in New Brunswick, N.J., has brands including Neutrogena and Band-Aid.

The deal is expected to close in the third quarter.

Johnson & Johnson said that the transaction isn’t expected to impact its previously announced full-year sales and earnings forecasts.

J&J shares rose 47 cents to $113.25 in morning trading Thursday. Its shares are up more than 13 percent over the past year.

Source: Associated Press via Salt Lake Tribune

comments closed

Related News

May 4, 2024

Novartis acquires Mariana in $1.75bn deal to strengthen radioligand portfolio

Life sciences

Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.

May 4, 2024

Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1

Life sciences

The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.

May 4, 2024

Ono Pharmaceutical acquires cancer-focused biopharma Deciphera for $2.4bn

Life sciences

Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.

How can we help you?

We're easy to reach